Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SARS1 | P49591 | 1/20 | 0.85 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.84 |
| ▸ | TARS1 | P26639 | 2/20 | 0.78 |
| ▸ | MARS1 | P56192 | 1/20 | 0.78 |
| ▸ | RARS1 | P54136 | 1/20 | 0.77 |
| ▸ | IARS1 | P41252 | 1/20 | 0.75 |
| ▸ | HARS1 | P12081 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178823 | 1.00 | SARS1 (0.85) | SARS1LARS1TARS1MARS1RARS1 | |
| SCHEMBL30270578 | 0.93 | SARS1 (0.85) | SARS1LARS1TARS1MARS1RARS1 | |
| SCHEMBL5063189 | 0.92 | SARS1 (0.82) | SARS1LARS1TARS1MARS1RARS1 | |
| SCHEMBL5063184 | 0.92 | SARS1 (0.82) | SARS1LARS1TARS1MARS1RARS1 | |
| SCHEMBL3187637 | 0.92 | SARS1 (0.87) | SARS1LARS1TARS1MARS1RARS1 | |
| SCHEMBL21068060 | 0.92 | SARS1 (0.87) | SARS1LARS1TARS1MARS1RARS1 | |
| SCHEMBL3187665 | 0.92 | SARS1 (0.87) | SARS1LARS1TARS1MARS1RARS1 | |
| SCHEMBL21067959 | 0.92 | SARS1 (1.00) | SARS1LARS1TARS1MARS1RARS1 | |
| SCHEMBL4313369 | 0.92 | SARS1 (1.00) | SARS1LARS1TARS1MARS1RARS1 | |
| Leusa SCHEMBL29562511 | 0.91 | LARS1 (1.00) | SARS1LARS1TARS1MARS1RARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | SARS1 32/4885LARS1 56/4885TARS1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.